Reza Yaesoubi, PhD
Associate Professor of Public Health (Health Policy)Cards
Additional Titles
Affiliated Faculty, Yale Institute for Global Health
Affiliated Faculty, Yale Institute for Foundations of Data Science
Contact Info
About
Titles
Associate Professor of Public Health (Health Policy)
Affiliated Faculty, Yale Institute for Global Health; Affiliated Faculty, Yale Institute for Foundations of Data Science
Biography
Dr. Yaesoubi is a health decision scientist with focus on developing and applying analytical methods to inform decision making in public health and medicine. His expertise is in developing methods to guide decisions when the evidence base and data are shifting too quickly for any static policy or guideline to suffice (e.g., during outbreaks of novel pathogens or spread of antimicrobial-resistant pathogens). Through incorporating computer simulation models, statistical and machine learning methods, and optimization techniques, he has developed mechanisms to combine data and evidence from disparate sources to inform cost-effective decisions in real-time. He has applied these methods to optimize public health responses to the spread of drug-resistant tuberculosis, antimicrobial-resistant gonorrhea, COVID-19, influenza, and meningitis. He is also interested in and contributed to the theoretical and methodological issues in medical decision-making and health care resource allocation.
Appointments
Health Policy & Management
Associate Professor on TermPrimaryInstitution for Social and Policy Studies
Assistant ProfessorSecondary
Other Departments & Organizations
Education & Training
- Post-Doctoral Research Fellow
- Brigham and Women’s Hospital (2014)
- Post-Doctoral Research Staff
- IBM Research (2011)
- Post-Doctoral Research Fellow
- Brigham and Women’s Hospital (2010)
- PhD
- North Carolina State University, Industrial and Systems Engineering (2010)
- MSc
- North Carolina State University, Industrial and Systems Engineering (2006)
- BS
- Sharif University of Technology, Industrial Engineering (2004)
Research
Overview
Medical Subject Headings (MeSH)
ORCID
0000-0002-9276-5750
Research at a Glance
Yale Co-Authors
Publications Timeline
Research Interests
Ted Cohen, DPH, MD, MPH
Arjun Venkatesh, MD, MBA, MHS
Howard Forman, MD, MBA, FACR
Long H. Tu, MD, PhD
Dhasakumar Navaratnam, MD, PhD
Kevin Sheth, MD
Cost-Benefit Analysis
Epidemics
Tuberculosis
Gonorrhea
Influenza, Human
Computer Simulation
Publications
2024
Personalizing the empiric treatment of gonorrhea using machine learning models
Murray-Watson R, Grad Y, St. Cyr S, Yaesoubi R. Personalizing the empiric treatment of gonorrhea using machine learning models. PLOS Digital Health 2024, 3: e0000549. PMID: 39141668, PMCID: PMC11324139, DOI: 10.1371/journal.pdig.0000549.Peer-Reviewed Original ResearchConceptsGonococcal Isolate Surveillance ProjectTreatment of gonorrheaEmpirical treatmentAntimicrobial-resistantNational surveillance systemEffects of first-line therapyEmpirical treatment of gonorrhoeaPrevalence of antimicrobial-resistantPrevalence of resistant strainsStandard guidelinesFirst-line therapyResistant to ciprofloxacinFirst-line antibioticsRecommended first-line antibioticsEmergence of antimicrobial-resistantPatients' basic characteristicsStrains of Neisseria gonorrhoeaeSurveillance projectPrescribing effective treatmentCeftriaxoneGonorrheaRecommended treatmentEffective treatmentPersonalized treatmentCefiximeNet Monetary Benefit Lines Augmented with Value-of-Information Measures to Present the Results of Economic Evaluations under Uncertainty
Yaesoubi R, Kunst N. Net Monetary Benefit Lines Augmented with Value-of-Information Measures to Present the Results of Economic Evaluations under Uncertainty. Medical Decision Making 2024, 44: 770-786. PMID: 39056310, DOI: 10.1177/0272989x241262343.Peer-Reviewed Original ResearchCitationsAltmetricConceptsResults of cost-effectiveness analysesNet monetary benefitCost-effectiveness planeCost-effectiveness analysisMonetary benefitsDecision uncertaintyDecision problemEffect estimatesHypothetical decision problemResults of economic evaluationsValue-of-informationDecision makersCost-effectiveness ratioEconomic evaluation studiesCorrelated costsHigh varianceLevel of uncertaintyParameter uncertaintiesEconomic evaluationMagnitude of parametersMakersDecisionUncertaintyCostMonetaryAssessing thresholds of resistance prevalence at which empiric treatment of gonorrhea should change among men who have sex with men in the US: A cost-effectiveness analysis
Yin X, Li Y, Rönn M, Li S, Yuan Y, Gift T, Hsu K, Salomon J, Grad Y, Yaesoubi R. Assessing thresholds of resistance prevalence at which empiric treatment of gonorrhea should change among men who have sex with men in the US: A cost-effectiveness analysis. PLOS Medicine 2024, 21: e1004424. PMID: 38976754, PMCID: PMC11262662, DOI: 10.1371/journal.pmed.1004424.Peer-Reviewed Original ResearchAltmetricConceptsDrug susceptibility testingQuality-adjusted life yearsFirst-line therapyFirst-line antibioticsNet health benefitFirst-lineRetreatment regimensResistance prevalenceRapid drug susceptibility testingRate of treatment failureTreatment of gonorrheaIncidence of gonorrheaAssociated with gonorrheaEmpirical therapyTreatment failureEmpirical treatmentGonococcal infectionSusceptibility testingGonorrhea casesMSM populationGonorrheaCost-effectiveness analysisDiagnostic testsResistant strainsTherapyHow many Monte Carlo samples are needed for probabilistic cost-effectiveness analyses?
Yaesoubi R. How many Monte Carlo samples are needed for probabilistic cost-effectiveness analyses? Value In Health 2024, 27: 1553-1563. PMID: 38977192, DOI: 10.1016/j.jval.2024.06.016.Peer-Reviewed Original ResearchConceptsProbabilistic sensitivity analysesIncremental cost-effectiveness ratioProbabilistic cost-effectiveness analysisCost-effectiveness analysisEstimate incremental cost-effectiveness ratiosIncremental cost-effectiveness ratio estimatesCost-effectiveness ratioDecision optionsStochastic modelPresence of parameter uncertaintiesCostParameter uncertaintiesUncertaintyLevel of accuracyInequalitySensitivity analysisEstimationMonteModelMonte Carlo samplingParameter samplesChebyshev inequalityImpact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis in Moldova: A mathematical modeling analysis.
James L, Klaassen F, Sweeney S, Furin J, Franke M, Yaesoubi R, Chesov D, Ciobanu N, Codreanu A, Crudu V, Cohen T, Menzies N. Impact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis in Moldova: A mathematical modeling analysis. PLOS Medicine 2024, 21: e1004401. PMID: 38701084, PMCID: PMC11101189, DOI: 10.1371/journal.pmed.1004401.Peer-Reviewed Original ResearchAltmetricConceptsQuality-adjusted life yearsStandard of careDrug susceptibility testingRifampicin-resistant tuberculosisRR-TBEnd-of-treatmentLonger regimensTreatment strategiesTreatment outcomesBurden of drug-resistant TBCost-effective treatment strategyResistance to amikacinDrug-resistant TBSevere adverse eventsHistory of TBResistance to delamanidTB drug resistanceAnti-TB drugsLifetime costsAssociated treatment outcomesFQ-R.Average timeNatural history of TBFluoroquinolone resistanceFQ-RReply to "Considering Health Systems Worldwide: Point of View From a Middle-Income Country".
Tu L, Melnick E, Venkatesh A, Sheth K, Navaratnam D, Yaesoubi R, Forman H, Mahajan A. Reply to "Considering Health Systems Worldwide: Point of View From a Middle-Income Country". American Journal Of Roentgenology 2024, 222: e2430900. PMID: 38294162, DOI: 10.2214/ajr.24.30900.Peer-Reviewed Original Research
2023
Cost-Effectiveness of CT, CTA, MRI, and Specialized MRI for Evaluation of Patients Presenting to the Emergency Department With Dizziness.
Tu L, Melnick E, Venkatesh A, Sheth K, Navaratnam D, Yaesoubi R, Forman H, Mahajan A. Cost-Effectiveness of CT, CTA, MRI, and Specialized MRI for Evaluation of Patients Presenting to the Emergency Department With Dizziness. American Journal Of Roentgenology 2023, 222: e2330060. PMID: 37937837, DOI: 10.2214/ajr.23.30060.Peer-Reviewed Original ResearchCitationsAltmetricConceptsQuality-adjusted life yearsEvaluation of patientsSecondary prevention measuresEmergency departmentProbabilistic sensitivity analysesConventional MRICumulative quality-adjusted life yearsCost-effective strategyIncremental costNoncontrast CT headAcute stroke treatmentSpecialized MRISelection of patientsHigher quality-adjusted life yearsConventional brain MRIMarkov decision-analytic modelNon-contrast CTNoncontrast head CTHealthcare system perspectiveUse of MRIBase-case analysisPrevention measuresDecision analytic modelGreater quality-adjusted life yearsDeterministic sensitivity analysesThe Impact of Rapid Drug Susceptibility Tests on Gonorrhea Burden and the Life Span of Antibiotic Treatments: A Modeling Study Among Men Who Have Sex With Men in the United States
Yaesoubi R, Xi Q, Hsu K, Gift T, St. Cyr S, Rönn M, Salomon J, Grad Y. The Impact of Rapid Drug Susceptibility Tests on Gonorrhea Burden and the Life Span of Antibiotic Treatments: A Modeling Study Among Men Who Have Sex With Men in the United States. American Journal Of Epidemiology 2023, 193: 17-25. PMID: 37625444, PMCID: PMC10773484, DOI: 10.1093/aje/kwad175.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsRapid drug susceptibility testDrug susceptibility testGonorrhea casesSusceptibility testsFirst-line treatmentBurden of gonorrheaGonococcal infectionGonorrhoea transmissionAntibiotic treatmentPatient outcomesIndividualized treatmentLife spanDrug susceptibilityCare testRapid pointEffective life spanAntibiotic resistanceAntibioticsTest specificityGonorrheaMenCiprofloxacinTreatmentCorrect ascertainmentLong-term impactResistance-minimising strategies for introducing a novel antibiotic for gonorrhoea treatment: a mathematical modelling study
Reichert E, Yaesoubi R, Rönn M, Gift T, Salomon J, Grad Y. Resistance-minimising strategies for introducing a novel antibiotic for gonorrhoea treatment: a mathematical modelling study. The Lancet Microbe 2023, 4: e781-e789. PMID: 37619582, PMCID: PMC10865326, DOI: 10.1016/s2666-5247(23)00145-3.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsPrevalence of resistancePrimary outcomeGonococcal infectionGonorrhea treatmentCombination therapyAntibiotic resistanceResistance emergenceNew antibioticsNew drugsUrgent public health concernCombination therapy strategiesSexual activity groupsPopulation-level prevalencePublic health concernSecondary outcomesAnnual incidenceGonorrhoea transmissionCurrent therapiesMSM populationUS CentersMathematical modelling studyCurrent drugsUS populationNeisseria gonorrhoeaeInfectious diseasesCT With CTA Versus MRI in Patients Presenting to the Emergency Department With Dizziness: Analysis Using Propensity Score Matching.
Tu L, Navaratnam D, Melnick E, Forman H, Venkatesh A, Malhotra A, Yaesoubi R, Sureshanand S, Sheth K, Mahajan A. CT With CTA Versus MRI in Patients Presenting to the Emergency Department With Dizziness: Analysis Using Propensity Score Matching. American Journal Of Roentgenology 2023, 221: 836-845. PMID: 37404082, DOI: 10.2214/ajr.23.29617.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsSecondary stroke prevention medicationsStroke prevention medicationsEmergency departmentPrevention medicationsEchocardiography evaluationPosterior circulation strokeProportion of patientsGroup of patientsPhysical examination findingsNeuroimaging resultsUse of MRIReview of systemsGreater frequencyPropensity-score matchingExamination findingsRetrospective studyED readmissionMedical historyHead CTClinical impactMRI examinationsBrain MRINeck CTADizzinessPatients
News & Links
Media
News
- October 31, 2024
Antibiotic Resistance: Fighting a Global Threat With ‘Phage-hunting’ and More
- June 30, 2022
Machine Learning Model Helps Identify Resistance to Key Antibiotics for Treating Tuberculosis
- May 02, 2022
Fetal Alcohol Exposure Data Underscore Need For Public Health Interventions
- July 01, 2021Source: Health Day
Alcohol Still a Threat in Too Many American Pregnancies: Study